Roshani Sinha

All Publications

• Novel Humanized Loss-of-Function NF1 Mouse Model of Juvenile Myelomonocytic Leukemia Sinha, R., Patil, R., Romano, R., Lee, E., Yao, Z., Liu, Y., Porteus, M. H., Bertaina, A. AMER SOC HEMATOLOGY. 2022: 9765-9766

  View details for DOI 10.1182/blood-2022-167413

  View details for Web of Science ID 000893230302333

• Aberrant Histone Landscape in Juvenile Myelomonocytic Leukemia Sinha, R., Dvorak, M., Niemeyer, C. M., Sakamoto, K. M., Patil, R., Jutz, P., Liu, Y., Kuo, A., Bertaina, A. AMER SOC HEMATOLOGY. 2021

  View details for DOI 10.1182/blood-2021-152074

  View details for Web of Science ID 000835740101069

• Development of embryonic and adult leukemia mouse models driven by MLL-ENL translocation EXPERIMENTAL HEMATOLOGY Sinha, R., Porcheri, C., d'Altri, T., Gonzalez, J., Ruiz-Herguido, C., Rabbitts, T., Espinosa, L., Bigas, A. 2020; 85: 13–19

  Abstract

  Rearrangements involving the mixed lineage leukemia gene (MLL) are found in the majority of leukemias that develop within the first year of age, known as infant leukemias, and likely originate during prenatal life. MLL rearrangements are also present in about 10% of other pediatric and adult acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). These translocations and others occurring in early life are associated with a dismal prognosis compared with adult leukemias carrying the same translocations. This observation suggests that infant and adult leukemias are biologically distinct but the underlying molecular mechanisms for these differences are not understood. In this work, we induced the same MLL chromosomal translocation in the embryo at the time of fetal liver hematopoiesis and in the adult hematopoietic tissues to develop disease models in mice that recapitulate human infant and adult leukemias, respectively. We successfully obtained myeloid leukemia in adult mice after MLL-ENL recombination induction using the interferon inducible Mx1-Cre line. Using this same Cre line, we generated embryonic MLL-ENL leukemias, which were more aggressive than the corresponding adult leukemias. In conclusion, we have developed a novel MLL-ENL embryonic leukemia model in mice that can be used to study some aspects of infant leukemia ontogeny.

  View details for DOI 10.1016/j.exphem.2020.04.008

  View details for Web of Science ID 000541254100004

  View details for PubMedID 32437911

• Notch ligand Dll4 impairs cell recruitment to aortic clusters and limits blood stem cell generation. The EMBO journal Porcheri, C., Golan, O., Calero-Nieto, F. J., Thambyrajah, R., Ruiz-Herguido, C., Wang, X., Catto, F., Guillén, Y., Sinha, R., González, J., Kinston, S. J., Mariani, S. A., Maglitto, A., Vink, C. S., Dzierzak, E., Charbord, P., Göttgens, B., Espinosa, L., Sprinzak, D., Bigas, A. 2020; 39 (8): e104270

  Abstract

  Hematopoietic stem cells (HSCs) develop from the hemogenic endothelium in cluster structures that protrude into the embryonic aortic lumen. Although much is known about the molecular characteristics of the developing hematopoietic cells, we lack a complete understanding of their origin and the three-dimensional organization of the niche. Here, we use advanced live imaging techniques of organotypic slice cultures, clonal analysis, and mathematical modeling to show the two-step process of intra-aortic hematopoietic cluster (IACH) formation. First, a hemogenic progenitor buds up from the endothelium and undergoes division forming the monoclonal core of the IAHC. Next, surrounding hemogenic cells are recruited into the IAHC, increasing their size and heterogeneity. We identified the Notch ligand Dll4 as a negative regulator of the recruitment phase of IAHC. Blocking of Dll4 promotes the entrance of new hemogenic Gfi1+ cells into the IAHC and increases the number of cells that acquire HSC activity. Mathematical modeling based on our data provides estimation of the cluster lifetime and the average recruitment time of hemogenic cells to the cluster under physiologic and Dll4-inhibited conditions.

  View details for DOI 10.15252/embj.2019104270

  View details for PubMedID 32149421

  View details for PubMedCentralID PMC7156969